New drug combo aims to stop Leukemia's return after transplant
NCT ID NCT05270200
Summary
This study is testing whether a combination of two drugs, azacitidine and chidamide, can help keep high-risk acute myeloid leukemia (AML) from coming back after a patient has received a stem cell transplant from a donor. The main goals are to see if this maintenance therapy is safe and if it can prevent relapse. About 20 adults who have recently had a transplant will receive the drug combination for up to one year and be closely monitored.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for LEUKEMIA, MYELOID, ACUTE are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Nanfang Hospital of Southern Medical University
RECRUITINGGuanzhou, Guandong, 510250, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.